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Abstract
Composite tissue allotransplantation (CTA) research faces two critical chal-
lenges. Firstly, the most applicable experimental model(s) in which CTA tol-
erance induction regimens should be characterized and tested requires 
clarification. Secondly, it has not been determined what would consti-
tute a suitable endpoint for clinical trials of such methodologies before 
progression toward wider clinical application could be considered appro-
priate. Currently, the most reliable method to induce CTA tolerance in ani-
mals is to establish mixed hematopoietic chimerism using bone marrow 
transplantation (BMT) from an allogeneic donor. This approach has three 
important constraints: (i) the requirement for toxic myeloablative condi-
tioning; (ii) a prerequisite 28-day delay period between BMT and CTA; and 
(iii) the potential for inducing graft-versus-host disease (GVHD). We review 
the history of chimerism induction for CTA, the strategies that have been 
proposed to circumvent CTA-related problems, and the insights that have 
been gained from our own research into these issues. The benefits of vascu-
larized BMT (VBMT) over conventional BMT for inducing CTA tolerance are 
highlighted. The establishment of mixed chimerism and the induction of 
tolerance require further research and refinement before they can be 
applied clinically. A safe and robust method of tolerance induction encour-
ages wider application of reconstructive CTA with fewer ethical obstacles. 
[Tzu Chi Med J 2008;20(2):101–108]
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1. Introduction
Composite tissue allotransplantation (CTA) has the 
potential to revolutionize reconstructive surgery for 
complex tissue defects and lost limbs. The feasibility 
and benefits of CTA have been demonstrated in ani-
mals, in 26 human recipients of hand transplants and 
in two human recipients of partial face transplants [1]. 
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CTA recipients currently require nonspecific immuno-
suppression to prevent transplant rejection. The tox-
icities associated with these agents are substantial, 
including opportunistic infections, increased rates of 
malignancies and end-organ failure [2]. Furthermore, 
these agents do not control against chronic rejection, 
which remains the most common cause of late graft 
loss [3]. CTA is generally indicated for functional and/
or esthetic enhancement, not for prolonging or sav-
ing lives. Ethical considerations regarding the cost as 
well as morbidity and mortality rates associated with 
nonspecific immunosuppression have limited the 
widespread clinical application of CTA.
2. Tolerance to CTA through mixed 
chimerism
Various methods to induce donor-specific transplan-
tation tolerance have been reported for experimental 
solid organ, composite tissue allotransplants and other 
allotransplants. The successful induction of donor-
specific tolerance in CTA recipients might theoretically 
overcome the limitations noted above. One robust 
approach to induce donor-specific tolerance is through 
bone marrow transplantation (BMT). Bone marrow 
chimerism results from the engraftment of hematopoi-
etic stem cells (HSCs) [4]. Chimerism refers to the 
harmonious coexistence of tissues from different 
animals of the same or different species [5]. The first 
demonstration of this type of tolerance was reported 
in 1953 by Billingham, Brent and Medawar [6]. Immu-
nosuppression is not required to prevent transplant 
rejection once engraftment has been established. 
Critical to this concept is the fact that bone marrow 
chimerism confers rejection-free transplant accept-
ance for highly antigenic tissues such as those from 
allogeneic skin, heart, and lung [7–9].
Donor-specific transplantation tolerance through 
chimerism can usually be achieved by one of two fol-
lowing approaches: full chimerism and mixed chi-
merism. Their differences are important to CTA. The 
level of chimerism in animals refers to the percentage 
of donor cells in peripheral blood lymphocytes as 
determined by flow cytometric analysis. In full chi-
merism, transplantation of major histocompatibility 
complex (MHC)-disparate bone marrow cells into ab-
lated recipients results in donor-specific transplanta-
tion tolerance. However, recipients are relatively 
immunoincompetent and readily susceptible to graft-
versus-host disease (GVHD) [10,11]. In addition, full 
chimerism is achieved at the cost of recipient ablation 
with significant morbidity and mortality [11]. In con-
trast, in mixed chimerism, the pluripotent HSCs of both 
the recipient and the donor coexist. Mixed chimerism, 
with levels of donor chimerism as low as 1%, also 
results in donor-specific transplantation tolerance and
offers a number of advantages over full chimerism [5]. 
Mixed chimeras exhibit superior immunocompetence 
for primary immune responses and are more resist-
ant to GVHD. Moreover, mixed chimerism can be es-
tablished with less toxic myeloablative conditioning. 
Native bone marrow provides host antigen present-
ing cells (APC) that are essential for full immunocom-
petence, while allogeneic bone marrow provides a 
persistent source of antigens for induction and main-
tenance of tolerance [12].
CTAs are comprised of a combination of skin, mus-
cle, nerves, tendons, and/or bone and bone marrow 
and may pose a formidable antigenic barrier to toler-
ance induction [13]. The first mixed chimerism exper-
iment involving CTA was performed in a rat model; 
chimerism was prepared using nonmyeloablative con-
ditioning with 500–700 cGy total body irradiation 
(TBI), anti-lymphocyte globulin (ALG) and tacrolimus. 
Sequential limb allografts were placed 12 months 
after BMT. In animals with > 60% early chimerism, no 
signs of rejection of the CTA were observed [13]. In 
sharp contrast, all animals with early chimerism, < 20% 
of the animals, developed moderate rejection clinically 
and histopathologically [13]. The results of these stud-
ies clearly demonstrated that chimerism could induce 
tolerance to highly antigenic CTA.
3. Problems of CTA through mixed 
chimerism
Mixed chimerism is the most reliable method of induc-
ing experimental transplantation tolerance. However, 
this approach has three important constraints: (i) the 
requirement for toxic myeloablative conditioning; (ii) 
a prerequisite 28-day delay period between BMT and 
CTA; and (iii) the potential for inducing GVHD. These 
limitations must be addressed if mixed chimerism is 
to be applied effectively for CTA tolerance induction 
in the clinical setting.
Recipient conditioning for HSC transplantation re-
quires two essential elements: (i) cytoreduction of the 
recipient marrow to create a space or niche [14]; and 
(ii) immunosuppression to prevent residual host cells 
from rejecting the donor transplant [15]. Prior to infus-
ing the host with donor bone marrow cells, the host 
must first be conditioned to create a space for engraft-
ment and the chimerism induction. This conditioning
is toxic to the host and often leads to immunoincom-
petence [16]. Myeloablative conditioning has thus been 
met with little enthusiasm amongst clinical transplan-
tologists. However, great advances have been made by 
hematologists/oncologists in their quest to develop 
less myeloablative conditioning strategies [17]. These 
efforts have opened new doors to novel and less toxic 
antigen-specific approaches of conditioning recipi-
ents for engraftment of HSCs. Another method is to 
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manipulate the recipient to become hyporesponsive 
to the transplanted bone marrow until it can take hold
and induce a self-perpetuating state of deletional tol-
erance [18]. Manipulation of the recipient cell compo-
nents responsible for alloreactivity will create a more 
tolerogenic milieu for bone marrow engraftment. In 
a normal mouse model, chimerism has been achieved 
by nonmyeloablative conditioning using low-dose TBI, 
alkylating agents, and monoclonal antibody (mAb) 
treatments [18–20].
Costimulatory blockade during BMT may further 
reduce the need for myelotoxic therapy during condi-
tioning. It is well established that T cells require at 
least two signals from APC to be activated. In this situ-
ation, signal 1 is in the form of antigen presentation, 
and signal 2 involves the interaction of costimulatory 
molecules and their receptors between T cells and APC 
[21]. Delivery of signal 1 without signal 2 induces an-
ergy and immune deviation toward tolerance. By spe-
cifically targeting costimulatory molecules expressed 
on the T cells, peritransplant anergy can take place. 
CD28 is constitutively expressed on T cells and is up-
regulated during T cell activation. Blockade of CD28 
on T cells or its ligand B7 (CD80 or CD86) on APCs 
(signal 2) induces recipient hyporesponsiveness by 
way of functional inactivation, regulation, or clonal de-
letion in solid organ allograft recipients. A number of 
agents, such as anti-CD154 (CD44L) and anti-CD28, 
which act by non-overlapping mechanisms, have been 
tested alone and in combination with the overall goal 
to eliminate the need for TBI [22,23].
Conventional protocols for preparing mixed chime-
rism in animal studies involve sequential steps, namely, 
host conditioning, donor BMT, characterization of chi-
merism by flow cytometry (at 28 days) and CTA [24]. 
The delay period has been considered a requirement 
for engraftment and repopulation of donor BM cells in 
the host. If allotransplantation is performed before 
successful engraftment of donor BM, it may interfere 
with the establishment of tolerance. This delay period 
might be possible for living solid-organ transplanta-
tion, as a delay between bone marrow infusion and 
organ transplantation is permitted. For hand trans-
plantation, the hand is always harvested from a cadav-
eric donor; therefore, both the bone marrow and the 
hand would need to be transplanted simultaneously. 
This is why the 28-day delay presents an important 
limitation for clinical application in CTA.
One aspect of CTA that distinguishes it from most 
other forms of transplantation is the lymphoid burden 
in the allotransplant itself. The allogeneic lymphoid 
tissue will influence the conditioning approach for es-
tablishing chimerism. If tolerance induction by simul-
taneous placement of marrow plus CTA is considered, 
GVHD is a significant potential hazard [25]. GVHD is 
caused by the reactions of large numbers of immuno-
competent donor cells in the lymphoid tissue such as 
those present in the transplanted donor limb. Further 
research is urgently needed to circumvent the problems 
associated with mixed chimerism.
4. Solutions to the problems, including 
our own experiences
We used a rat CTA model in the transplantation of hind 
limb osteomyocutaneous (HOMC) flaps for the study 
of chimerism and tolerance with reference to the 
problems noted above [26]. Briefly, HOMC flap CTA 
harvest started with a longitudinal incision along 
the medial aspect of the lower leg from the ankle to 
the thigh (Fig. 1A). Circumferential skin incisions were 
made at the level of the mid-thigh and the ankle 
joints to preserve the cutaneous paddle (3 × 5 cm) in 
the lateral part of the lower leg. The femoral vessels 
were mobilized individually from the superficial epi-
gastric vessels to the inguinal ligament. Both the femur 
and tibia were then amputated distally to completely 
mobilize the lower limb segment based solely on the 
femoral vessels. The cutaneous part of the HOMC flap 
was based on the vascular supply from the lateral 
leg to facilitate insetting with the skin externalized. 
The limb and bone marrow in the medullary cavity 
were then flushed with heparinized saline. The HOMC 
flaps, weighing an average of 8 ± 1.5 g, were wrapped 
with wet gauze and placed in iced water. The recipient 
operation was started with a transverse incision in the 
inguinal region to expose and mobilize the femoral 
artery and vein just distal to the superficial epigas-
tric vessels and proximally up to the muscular branch 
to the gracilis. A 2 × 4 cm defect was created in the 
gluteal area to position the HOMC flap with sutures. 
The femoral vessels were anastomosed using micro-
surgical technique (10-0 nylon). The skin was closed 
using absorbable suture (5-0 Monocryl; Ethicon, 
Sommerville, NJ, USA). The CTA study protocols of 
conventional BMT and our recently developed vascu-
larized BMT (VBMT) for chimerism and tolerance in-
duction are depicted in Figs. 1B and 1C, respectively, 
for comparative purposes.
The rat offers significant advantages over the 
mouse for CTA study for the following reasons: (i) 
lower cost; (ii) hind limb transplantation is techni-
cally more feasible; and (iii) rats are more prone to 
develop GVHD than mice (making an evaluation of 
GVHD more similar to humans). In the rat, transplanta-
tion of unmodified marrow results in rapidly lethal 
GVHD [27]. Rat models have been previously utilized
for evaluating tolerance to lung [9], heart [28], tra-
chea [29], and limb transplants [13].
In a previous rat model, a minimum dose of 850 cGy 
TBI was required to achieve engraftment in 100% of 
rat recipients of marrow depleted of αβ-T cell recep-
tor (TCR)+ T cells [30]. The addition of ALG (10 mg on 
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day 5) plus FK506 (l mg/kg/day −1 through to day + 10) 
reduced the minimum TBI dose to 500 cGy [31]. The 
minimum dose of TBI could also be significantly re-
duced if an anti-NK mAb was administered [32]. The 
recent concept of costimulatory blockade during BMT 
may be used to reduce the need for myelotoxic therapy 
further during conditioning [33]. In a rat CTA model 
with CD28 blockade by administrating CTLA4-Ig at 
2 mg/kg per day (alternate days in combination with 
tacrolimus at 1 mg/kg daily from day 0 through to 
day + 10, and a single dose of 10 mg ALG on day + 10), 
the required TBI conditioning was as low as 300 cGy 
on day −1 [33]. Using the same rat surgical model, we 
took further specific measures in order to circumvent 
the problems associated with CTA, as follows.
4.1. Reducing alloreactivity can eliminate 
toxicity of myeloablative conditioning
Since the toxicity associated with these myeloabla-
tive agents remains a concern, the development of a 
less toxic nonmyeloablative conditioning is one of our 
main goals in CTA tolerance induction. Accordingly, 
the ad dition of cyclosporine (l6 mg/kg/day 0 to + 10) 
plus ALG (5 mg on day −1 and day + 10) could help 
donor marrow cells to engraft and create mixed chi-
merism. Cyclosporine can aid in the induction of mixed 
chimerism when using TBI as low as 200 cGy [34] 
(Fig. 2). Notably, our results showed a better accep-
tance rate of CTA at the dose of 400 cGy than previous 
results [31].
In our other study, fludarabine phosphate (Flu) was 
used to reduce the dose of TBI. Flu is one of the purine 
nucleoside analogs that have immunosuppressive ac-
tivity against lymphocytes by inhibiting DNA synthesis 
[35] and by inducing apoptosis [36]. CD4 and CD8 T 
cells are more sensitive to the effects of Flu than B 
cells [37,38]. By adding Flu, tolerance to CTA can be 
achieved by further reduction of TBI down to 200 cGy 
[34] (Fig. 3). The development of less toxic immuno-
suppressive and/or tolerizing strategies render the re-
cipient hyporesponsive to the donor at the time of 
transplantation, thereby theoretically allowing the re-
duction of TBI or dose of the myelotoxic agent. In the 
future, the use of costimulatory blockade, infusion 
of ex vivo expanded immature dendritic cells cocul-
tured with donor T cells, or facilitating cells (FLs) [10], 
Fig. 1 — (A) Schematic presentation of the transplantation of hind limb osteomyocutaneous (HOMC) flaps from a donor 
Brown Norway (RT1AC) rat to a recipient Lewis (RT1Al) rat. The hind limb flap was harvested and tailored to the osteo-
myocutaneous flap with the preservation of a 3 ´  2 cm skin paddle in the lower posterior limb. Femoral vessels as the 
recipient vessels were anastomosed. The flap of the donor rat was inset in the back of the recipient with easy access for 
daily monitoring of rejection. See the text for details. (B) In conventional CTA protocol of BMT to induce chimerism and 
tolerance, recipient rats were conditioned with total body irradiation (TBI), transplanted with 100 ´  106 bone marrow 
cells with T-cell depletion from donors, and given cyclosporine (l6 mg/kg/day 0 to + 10) plus ALG (5 mg on days 1 and 10). 
HOMC flap transplantation was carried out between days 29 and 35. Characteristics of engraftment and chimerism 
level in recipient rats were monitored periodically until the end of the observation period. (C) In the protocol of vas-
cularized BMT (VBMT) to induce chimerism and tolerance, recipient rats were conditioned with TBI, transplanted with 
VBMT from donor HOMC flap on day 0, and given tacrolimus (1 mg/kg/day) or cyclosporine (l6 mg/kg/day 0 to + 10) 
plus ALG (5 mg on days 1 and 10). Characteristics of engraftment and chimerism level in recipient rats were monitored 
periodically until the end of the observation period.
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or infusion of donor-specific regulatory T cells (Treg) 
sorted from stable chimera could be used to render 
host-versus-graft (HVG) reactivity in the recipient more 
hyporesponsive. In this way, the myelotoxic TBI dose 
can be largely reduced.
4.2. VBMT can simultaneously induce mixed 
chimerism and tolerance to CTA
To overcome the 28-day delay for tolerance induction 
to CTA in rats, we used VBMT to simultaneously induce 
mixed chimerism and tolerance to CTA. We treated 
the recipient rats using TBI at different doses (600, 
400, 200 cGy) alongside tacrolimus and ALG. Complete 
acceptance of syngeneic transplants and short-term 
survival of allogeneic transplants without any immu-
nosuppression were observed, and tolerance was 
induced in 37.5% of the animals using 600 cGy TBI 
and in 16.7% of the animals using 400 cGy TBI. 
These animals with tolerant CTAs survived until the 
end of the 150-day observation period [38] (Fig. 4). 
Tolerance was induced in 33% of the rats using 
200 cGy in VBMT and in 0% of the rats using 200 cGy 
TBI in BMT [39] (Fig. 5). Our results indicated that 
donor bone marrow cells, which are released from 
vascularized bone transplants, may have also con-
tributed to the induction of mixed chimerism. In addi-
tion, HSCs in the bone marrow cavity of VBMTs 
downmodulated host immune responses and in-
duced tolerance. Collectively, VBMT in CTA directly 
offers bone marrow niches for HSCs and auto-induces 
Fig. 3 — Reducing alloreactivity can eliminate toxicity of 
myeloablative conditioning. Flu acts against CD4 and CD8 
T cells. Injection of Flu at day -1 can further reduce TBI 
dose down to 200 cGy, and induce tolerance to CTA as 
effectively as the use of TBI alone at a dose of 400 cGy.
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Fig. 4 — VBMT can simultaneously induce mixed chime-
rism and tolerance to CTA. VBMT can induce tolerance 
to allotransplants after nonmyeloablative immunomodu-
lation. The survival of each allotransplant was analyzed 
and recorded. The syngeneic transplant was not rejected 
clinically, whereas the allogeneic transplant was rejected 
within 14 days. When tolerance was created by immu-
nomodulation, the survival of grafts could be prolonged 
until the end of the observation period indicated at the 
doses of 400 and 600 cGy TBI.
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Fig. 2 — Cyclosporine replaces tacrolimus-based nonmy-
eloablative conditioning. We used donor Brown Norway 
(RT1AC) and recipient Lewis (RT1Al) strains. The level 
of chimerism refers to the percentage of donor cells in 
peripheral blood lymphocytes based on dual-color flow 
cytometric analysis, as exemplified in the upper right 
corner (upper frame). Characteristics of engraftment and 
chimerism level in rats 1 month after being conditioned 
with TBI at 200, 400 and 600 cGy, transplanted (i.p.) with 
100´ 106 bone marrow cells T cell depletion (TCD) from 
donor rats, and given 16 mg/kg cyclosporine (s.c.) between 
day 0 and day 10, and 5 mg ALG (i.p.) at day -1 and at day 
+ 10 (lower frame). Note that the levels of donor chimerism 
correlate with the amount of conditioning.
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donor-specific tolerance to its allotransplants without 
the 28-day delay period.
4.3. Immunomodulation of donor 
allotransplants plays an important 
role in reducing GVHD
GVHD is mediated by immunocompetent donor cells 
that initiate a rejection response against the recipient. 
T cells have been identified as the most important 
effector cellular subset in this reaction [40], although 
other cell populations may also participate [41]. Re-
moval of mature T cells from the transplanted bone 
marrow graft has prevented GVHD effectively in mice, 
rats and humans [27].
GVHD can be initiated by mature T cells from the 
donor bone marrow or those present in the trans-
planted donor limb. We found that depletion of both 
αβ T cells and γδ T cells from the donor marrow inocu-
lum prevented GVHD, implicating a role for both types 
of T cells as effectors in GVHD. Importantly, this ap-
proach to T cell depletion does not remove facilitating 
cells (FC) [10], nor does it compromise engraftment. 
Interestingly, the phenotype of FCs is not dissimilar 
to that of plasmacytoid DCs [42]. Plasmacytoid DCs are 
known to mediate antigen-specific tolerance and in-
duce CD4+ as well as CD8+ regulating T cells in vitro
[43,44]. For VBMT to induce tolerance, graft perfusion 
with anti-T cell receptor mAb can immunomodulate 
the bone graft to protect the lethally irradiated rats with 
CTA from GVHD and concomitantly induce long-term 
donor-specific tolerance to CTA [45] (Fig. 6).
There is much room for further research in the re-
lief of GVHD. A great deal of attention has recently 
been paid to the preparation of specific cell popula-
tions that promote tolerance, notably plasmacytoid 
dendritic cells, HSC and mesenchymal stem cells 
(MSC). Infusion of large numbers of allogeneic FCs, 
HSCs or MSCs can make chimerism and tolerance to 
CTA less toxic [42,46]. Infusion of MSCs from a third 
party as the source has also been observed to lessen 
GVHD in allogeneic bone marrow transplantation in 
leukemia patients [47,48; Lung-Ji Chang, personal 
communication]. In fact, MSCs have been used to fa-
cilitate the induction of mixed hematopoietic chimer-
ism and islet allograft tolerance without GVHD in rats 
[49]. Encouraging results obtained along these lines 
of investigation have affected a number of biomedi-
cal disciplines, including regeneration medicine, tissue 
engineering, hematology/oncology, cell therapy and 
transplantation. Lastly, it is also important to develop 
patient monitoring measures, which can be used to 
reflect a success or failure of tolerance induction to 
CTA during and after treatment for individual patients. 
One should be able to develop such tests based on 
Fig. 6 — Immunomodulation of donor allotransplant plays 
an important role in avoiding GVHD. Recipients were pre-
conditioned with 950 cGy TBI on day -1. Experimental 
groups were: Group I: irradiation without allotransplanta-
tion, Group II: syngeneic hind limb osteomyocutaneous 
(HOMC) flap transplantation, Group III: allogeneic HOMC 
flap transplantation, Group VI: allogeneic hind limb HOMC 
flap perfused with anti-TCR mAb into the graft before 
transplantation. All of the rats died within 12 days after 
950 cGy. Syngeneic and allogeneic hind limb HOMC flap 
could rescue the rats after lethal irradiation. Allogeneic 
hind limb HOMC flap transplantation in Group III induced 
GVHD, which led to death at around 3 weeks after trans-
plantation. In contrast, HOMC flap perfused with anti-ab-TCR 
mAb avoided GVHD and created tolerance in the recipient 
rats. Thus, rats in Group IV experienced long-term survival 
of allotransplants.
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Group VI: 400 cGy plus VBMT. All recipients were treated 
with cyclosporine 16 mg/kg/day between day 0 and day 
10, and ALS 5 mg on day -1 and day + 10. Tolerance was 
induced in 33% of the rats with 200 cGy in VBMT, but 0% 
of the rats with 200 cGy TBI.
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animal models of CTA via mixed chimerism. These 
tests should eventually be considered an integral part 
of the protocols to be used clinically for CTA.
5. Conclusions
CTA continues to face histocompatibility and immu-
nogenicity problems. Modern immunosuppressive reg-
imens are used to maintain the function and viability 
of the CTA. The side effects of chronic immunosuppres-
sion and the uncertainty of long-term outcomes due to 
chronic rejection have limited the clinical application 
of CTA. Tolerance induced by mixed chimerism, in-
stead of relying on chronic immunosuppression, will 
be a major departure from the current clinical practice 
in CTA recipients. Effective means of depleting T cells, 
development of humanized mAbs to human T cells 
and to costimulatory molecules, and expansion of FCs 
and HSCs raise hopes that advancements made in 
rodent models will soon be applicable to large animal 
models and humans. Efforts should also be directed 
towards the generation of new biologicals through the 
collaboration of academic centers and biopharma-
ceutical companies. Further research is necessary to 
minimize CTA-associated immune response problems 
before CTA protocols can attain widespread clinical 
application. Our recent studies involving VBMT have 
offered an attractive surgical model to the study of 
CTA tolerance, which can be further manipulated in 
order to yield more satisfactory results. As early clinical 
trials lead to refinements, significant immunological 
and clinical benefits may soon be brought about for 
CTA patients.
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